Roy de Souza

Summary

BreakBio has a personalized immunotherapy for any cancer showing promising results in individual patients. The AI/ML platform designs a custom drug (BreakVax) for each patient. Raising capital for clinical trials. Every decade or two, a groundbreaking advance transforms cancer treatment. Keytruda unlocked immunotherapy's potential and now generates $25 billion annually. Its scale is possible because it works across many cancers. Traditional drugs target one protein found on cells in one cancer. Keytruda instead helps T-cells. These T-cells attack multiple targets found on the cancer cells of one patient, but different targets on the cells of the next patient. While effective, Keytruda relies on existing T-cells that may not recognize all parts of the cancer, leaving some cancer cells untouched. Yet immunotherapy drug development focuses mostly on new ways to help just the existing T-cells (LAG-3, TIGIT, ..). What if instead we build on Keytruda success and generate many new T- cells per patient to attack many new targets on their cancer cells? To do this, we must identify the millions of tiny, invisible peptides (small proteins) present on each patient’s cancer cells and choose good targets. BreakBio’s ML platform discovers 30 good targets for each patient and designs the personalized BreakVax drug to trigger T-cell generation. BreakVax personalized immunotherapy (sometimes known as a “personalized cancer vaccine”) treats patients who have cancer. Vaccines inject viral proteins in the arm to get the body to create antibodies or T-cells to fight those proteins. In cancer, the patient specific peptides (the targets) are injected into the arm stimulate the immune system to create new T- cells against that patient’s cancer cells. This personalized medicine works across multiple cancer types. There’s an opportunity for BreakBio to treat patients with many cancers at scale and become the next $25 billion blockbuster drug. Raising capital to initiate 4 randomized clinical trials with 4 opportunities for accelerated FDA approval.